Trial · NCT07905066
Hemophagocytic Lymphohistiocytosis After Allogeneic Stem Cell Transplantation
NCT07905066, Recruiting, Peking University People's Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Hemophagocytic Lymphohistiocytosis After Allogeneic Stem Cell Transplantation. Trials, record NCT07905066. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07905066
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Hemophagocytic Lymphohistiocytosis After Allogeneic Stem Cell Transplantation
- NCT number
- NCT07905066
- Status
- Recruiting
- Enrollment
- 10,000 participants, estimated
- Lead sponsor
- Peking University People's Hospital
- Conditions
- Hemophagocytic Lymphohistiocytosis (HLH)
- First posted
- 2026-10-29
- Last updated
- 2026-10-29
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Cumulative Incidence of First De Novo HLH Within 365 Days After Transplantation | From transplantation through day 365. | Cumulative incidence of the first adjudicated de novo HLH episode after first allogeneic hematopoietic stem cell transplantation. HLH requires at least five of the eight HLH-2004 criteria within the same clinical episode and confirmation by the adjudication group. The onset date is the first date the study definition is met. Death and second allogeneic transplantation before HLH are competing events. |
| Primary | Discrimination of the 7-Day HLH Risk Prediction Model | At evaluable assessments on days 1 to 358 after transplantation, with HLH occurrence evaluated over the subsequent 7 days, through day 365. | Time-dependent area under the receiver operating characteristic curve for predicting first HLH onset within the next seven days, evaluated separately in independent-center and prospective validation cohorts. Values range from 0 to 1, with higher values indicating better discrimination. Estimates account for the sampling design and follow-up. |
| Primary | Calibration of Predicted 7-Day HLH Risk | At evaluable assessments on days 1 to 358 after transplantation, with HLH occurrence evaluated over the subsequent 7 days, through day 365. | Agreement between predicted seven-day probabilities and observed seven-day HLH occurrence, evaluated using calibration curves in independent-center and prospective validation cohorts. Observed occurrence estimates account for the sampling design, follow-up, and competing events. |
| Primary | Positive Predictive Value of 7-Day HLH Alerts | At evaluable assessments on days 1 to 358 after transplantation, with HLH occurrence evaluated over the subsequent 7 days, through day 365. | Percentage of evaluable model-positive assessments followed by adjudicated first HLH onset within the next seven days. A positive assessment is defined using the prediction threshold fixed before validation. Estimates are adjusted for the sampling design and follow-up where applicable. |
| Primary | Case Detection Rate for Incident HLH | At evaluable assessments on days 1 to 358 after transplantation, with HLH occurrence evaluated over the subsequent 7 days, through day 365. | Percentage of adjudicated incident HLH cases with at least one model-positive assessment during the seven days before onset, among cases with an eligible pre-onset model assessment. The prediction threshold is fixed before validation. Estimates are adjusted for the sampling design and follow-up where applicable. |
| Secondary | Cumulative Incidence of HLH Within 100 Days After Transplantation | From transplantation through day 100. | Cumulative incidence of first adjudicated de novo HLH, using the same definition as the primary clinical outcome. Death and second allogeneic transplantation before HLH are competing events. |
| Secondary | All-Cause Mortality Within 28 Days After HLH Onset | From HLH onset through day 28 after onset. | Probability of death from any cause within 28 days after adjudicated HLH onset among participants who develop HLH. Follow-up time starts on the HLH onset date. |
| Secondary | All-Cause Mortality Within 60 Days After HLH Onset | From HLH onset through day 60 after onset. | Probability of death from any cause within 60 days after adjudicated HLH onset among participants who develop HLH. Follow-up time starts on the HLH onset date. |
| Secondary | All-Cause Mortality Within 90 Days After HLH Onset | From HLH onset through day 90 after onset. | Probability of death from any cause within 90 days after adjudicated HLH onset among participants who develop HLH. Follow-up time starts on the HLH onset date. |
| Secondary | Overall Survival at One Year After Transplantation | From transplantation through day 365. | Probability of survival one year after first allogeneic hematopoietic stem cell transplantation. Death from any cause is the event, and follow-up time starts on the transplantation date. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07905066
GET https://conductscience.org/api/trials/v1/NCT07905066/registered